Update shared on09 Sep 2025
Fair value Decreased 25%The significant reduction in Q-linea’s consensus price target reflects a notably lower future P/E ratio, indicating reduced expectations for earnings growth or valuation, with the fair value now set at SEK60.00.
What's in the News
- Q-linea and BLASTID announced successful proof-of-concept for ultra-rapid direct-from-whole-blood organism isolation, enrichment, and phenotypic antibiotic susceptibility testing (AST).
- Their combined technology delivers clinically actionable results, including minimum inhibitory concentration (MIC) values, in less than 8 hours from patient blood draw, even at very low pathogen concentrations.
- Initial trials focused on the clinically significant ESKAPE bacterial panel, using BLASTID’s SPLENDID platform and Q-linea’s ASTar instrument.
- The work was presented at the Association for Laboratory Medicine and Diagnostics (ADLM2025) Conference and partly funded by the US Government's ARPA-H.
Valuation Changes
Summary of Valuation Changes for Q-linea
- The Consensus Analyst Price Target has significantly fallen from SEK80.00 to SEK60.00.
- The Future P/E for Q-linea has significantly fallen from 23.01x to 17.22x.
- The Discount Rate for Q-linea remained effectively unchanged, moving only marginally from 5.86% to 5.78%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.